Cytokinetics, Incorporated (CYTK) NASDAQ
73.68
-3.08(-4.01%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
73.68
-3.08(-4.01%)
Currency In USD
| Previous Close | 76.76 |
| Open | 76.09 |
| Day High | 76.48 |
| Day Low | 73.18 |
| 52-Week High | 80.2 |
| 52-Week Low | 30.81 |
| Volume | 1.62M |
| Average Volume | 2.44M |
| Market Cap | 9.17B |
| PE | -10.76 |
| EPS | -6.85 |
| Moving Average 50 Days | 68.88 |
| Moving Average 200 Days | 61.58 |
| Change | -3.08 |
Cytokinetics Announces European Commission Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
GlobeNewswire Inc.
Feb 17, 2026 12:30 PM GMT
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Euro
Cytokinetics to Announce Fourth Quarter Results on February 24, 2026
GlobeNewswire Inc.
Feb 12, 2026 9:00 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time. Following the announcement,
Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program
GlobeNewswire Inc.
Feb 09, 2026 12:30 PM GMT
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eig